IPM Take
An outbreak becomes harder to control when emergency tools never become ordinary services.
Europe does not need another cycle of alarm followed by silence.
It needs mpox vaccination and testing to be reachable by people most likely to benefit, before exposure rather than after another cluster appears.
Executive Summary
ECDC’s August surveillance update reported 153 clade I mpox cases in July, compared with 159 in June and 162 in May.
Twenty countries reported more than 1,000 clade I cases during the preceding 12 months.
Transmission continues primarily among men who have sex with men, while ECDC identifies increasing vaccination uptake as one of the most important measures available to reduce transmission.
Why it matters
- Public authorities: Stable transmission is not elimination. Prevention has to become sustained rather than activated only when case numbers rise.
- Clinicians and sexual-health services: Testing, vaccination, contact management and non-judgmental care need to sit inside the same accessible pathway.
- Communities: Outreach must target epidemiological risk without turning affected groups into labels or sources of blame.
There is a dangerous way to read a stable epidemic curve.
Nothing is getting dramatically worse.
So nothing urgent needs to change.
Europe should resist that interpretation.
ECDC recorded 153 clade I mpox infections in July. June had 159. May had 162.
This is not explosive growth, and it should not be described as one.
But neither is the virus disappearing.
Transmission has settled into persistence.
That changes the implementation question.
When mpox was treated primarily as an emergency threat, governments could rely on temporary vaccination campaigns, specialist clinics and reactive contact management.
Persistent transmission requires something more durable.
Vaccination needs to become easier to access for people at substantially higher risk of exposure.
Testing needs to be straightforward.
Contact management needs to be rapid.
Sexual-health services need the capacity to deliver all three without creating unnecessary barriers.
A recommendation is not an access pathway.
A person needs to know they are eligible.
They need to know where vaccination is available.
Appointments need to exist.
Clinicians need to recognise the disease.
Laboratories need to return results quickly.
And communication must be specific enough to reach those at higher risk without becoming moralising or stigmatising.
The large majority of cases with complete information continue to be reported among men who have sex with men.
That epidemiological fact should guide service design.
It should not become social judgment.
That distinction matters.
Poorly targeted communication misses people.
Poorly framed communication drives them away.
European systems have had several years to learn that lesson.
The next phase of mpox control should therefore look less like emergency response and more like competent preventive healthcare: vaccination embedded into trusted services, sequencing of positive specimens, accessible diagnostics, rapid contact follow-up and community organisations treated as delivery partners rather than communications channels of last resort.
The curve is stable.
Policy should not be.
